Th2-biased anti-tumor immunity promotes glioma growth in a mouse model

Slides:



Advertisements
Similar presentations
John A. Barrett Ph.D. Ziopharm Oncology, Boston MA 02129
Advertisements

Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.
G-200 Partnering Opportunity March 2012 Contact: Jonae R. Barnes jonae
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Figure 3 Intracranial targeting of high-grade gliomas
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Fig. 8. In vivo suppression of MM by CMLD
H31m1-PDL1 cells form progressively growing tumors in WT mice.
The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.
Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.
Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Volume 16, Issue 11, Pages (September 2016)
Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.
Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. Immune-mediated.
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.
L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.
Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.
coTCRcys-transduced T cells control tumor growth in vivo.
The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.
Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.
Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.
Matriptase-2 inhibited breast tumor development in vivo.
PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.
Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.
ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,
Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy by Julia K. Tietze, Danice.
Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)
Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.
Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.
ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.
Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.
Influenza vaccine enhances NK cell function through IFN-α.
Derivation of the 4102 tumor cell lines.
Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.
MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.
Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.
Model of minimal residual disease.
A, TSG-6 staining in human prostate.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
In vivo effects of TTFields on intradermal tumors in mice.
Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.
Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.
T cells with a ROR1-specific CAR eliminate tumor cells in vivo only with a modified long spacer. T cells with a ROR1-specific CAR eliminate tumor cells.
Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.
CpG oligodeoxynucleotide (CpG ODN)–induced activation of different types of primary malignant B cells. CpG oligodeoxynucleotide (CpG ODN)–induced activation.
Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.
Levels of neutrophil infiltration into gliomas correlate with tumor grades and tumor progression. Levels of neutrophil infiltration into gliomas correlate.
LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.
BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.
Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)
Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.
Volume 25, Issue 4, Pages (April 2017)
Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.
Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.
Presentation transcript:

Th2-biased anti-tumor immunity promotes glioma growth in a mouse model Sami Sauma April 12,2016

Background – Astrocytoma Grade II low grade astrocytoma Grade III anaplastic astrocytoma Grade IV glioblastoma multiforme (GBM) Most common primary CNS tumor Aggressive, short clinical history, less than 3 months Aggressive; median survival 15 months

Background – Astrocytoma AIII CD163low CD163high AII AIII GBM Prosniak et al., 2013; Clin Cancer Res 19:3776-3786

Background – The Immune System Helper T Cell Zhu, 2008; Blood: 112 (5)

Background – The Immune System Alternatively Activated Monoctye Zhu, 2008; Blood: 112 (5)

Background – The Immune System Tumor Associated Macrophages

Background – GL261 Glioma Cell Line Commercialization NCI Repository Methylcholanthrene Seligman and Shear, 1939 Ex vivo transplantation Serial passaging Orthotopic Model Subcutaneous Model

Background – Antisense Oligodeoxynucleotides and the Tbet-/- Mouse (AS ODN) C57BL/6J Widely used inbred strain of mice Natural bias towards Th1 immunity Refractory to tumor development Antisense technology Tbet-/- C57BL/6 background A targeted mutation of the T-box transcription factor Tbx21 CD4 T cells do not produce the Th1-type cytokine interferon-γ Elevated levels of Th2-type cytokines

Background – Published Vaccine Data GL261 GL261 + AS ODN Gl261 (left flank) + AS ODN (right flank) Harshyne et al., 2015; Cancer Immunol Immunother 64(3):299–309 Morin-Brureau et al., 2015; Cancer Immunol Immunother 64(4):447-57

Results – Subcutaneous Model (Vaccine) GL261 GL261 + AS ODN GL261 GL261 + AS ODN

Results – Intracranial Titration of GL261

Results – Orthotopic Model Vaccine Intervention PBS GL261 + AS ODN PBS GL261 + AS ODN

Results – Orthotopic Model Vaccine Intervention PBS GL261 chambered + AS ODN PBS GL261 ch.+ AS ODN

Results – Orthotopic Model Vaccine Intervention PBS GL261 exosomes + AS ODN PBS GL261 exo + AS ODN

Results – Orthotopic Model PBS GL261 exo + AS ODN GL261 + AS ODN qPCR analysis of left and right cortices, and tumor tissue reveals no significant difference between two vaccination groups and mock. Elevated CD204 seen throughout.

Results – Subcutaneous Model PBS AS ODN Results – Subcutaneous Model AS ODN Intervention Day 0 flank administration of untreated GL261 cells in C57 and Tbet-/- mice Day 19/20 (dashed line) intraperitoneal injection of antisense or vehicle (PBS)

Results – Subcutaneous Model AS ODN Intervention PBS AS ODN

Results – Orthotopic Model AS ODN Intervention PBS AS ODN PBS AS ODN

Results – Orthotopic Model AS ODN Intervention PBS AS ODN PBS AS ODN

Results – Orthotopic Model AS ODN Intervention PBS AS ODN PBS AS ODN PBS AS ODN PBS AS ODN PBS AS ODN PBS AS ODN PBS AS ODN